These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1502902)

  • 21. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?
    Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A
    Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy.
    Nakajo M; Tsuchimochi S; Tanabe H; Nakabeppu Y; Jinguji M
    Ann Nucl Med; 2005 Jun; 19(4):297-308. PubMed ID: 16097639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease.
    Kim WB; Han SM; Kim TY; Nam-Goong IS; Gong G; Lee HK; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):719-25. PubMed ID: 15163336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
    Alexander EK; Larsen PR
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study.
    Peters H; Fischer C; Bogner U; Reiners C; Schleusener H
    Eur J Clin Invest; 1996 Jan; 26(1):59-63. PubMed ID: 8682157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.
    Chiovato L; Santini F; Vitti P; Bendinelli G; Pinchera A
    Clin Endocrinol (Oxf); 1994 Jun; 40(6):803-6. PubMed ID: 8033373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
    Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
    Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
    Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
    Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is standard 555 MBq 131I-therapy of hyperthyroidism ablative?
    Bertelsen J; Herskind AM; Sprogøe Jakobsen U; Hegedüs L
    Thyroidology; 1992 Dec; 4(3):103-6. PubMed ID: 1285034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for thyroid cancer according to French recommendations with thyroid ultrasound in newly diagnosed Graves' disease without palpable nodule is not useful.
    Nys P; Cordray JP; Sarafian V; Lefort-Mossé È; Merceron RÉ
    Ann Endocrinol (Paris); 2015 Feb; 76(1):13-8. PubMed ID: 25558015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytologic findings in thyroid nodules after 131I treatment of hyperthyroidism.
    Granter SR; Cibas ES
    Am J Clin Pathol; 1997 Jan; 107(1):20-5. PubMed ID: 8980362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroid nodules and thyroid cancer in Graves' disease.
    Tam AA; Kaya C; Kılıç FB; Ersoy R; Çakır B
    Arq Bras Endocrinol Metabol; 2014 Dec; 58(9):933-8. PubMed ID: 25627049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapse of Graves' disease 23 years after treatment with radioactive iodine (131I).
    Hegele RA; Volpé R
    J Clin Lab Immunol; 1985 Oct; 18(2):103-5. PubMed ID: 3841162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ; Ladenson PW
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease.
    Moura-Neto A; Mosci C; Santos AO; Amorim BJ; de Lima MC; Etchebehere EC; Tambascia MA; Ramos CD; Zantut-Wittmann DE
    Clin Nucl Med; 2012 Jun; 37(6):550-4. PubMed ID: 22614185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transient hypothyroidism after iodine-131 treatment of Graves' disease.
    Gómez JM; Virgili N; Soler J; Fernández M; Montaña E
    Thyroidology; 1989 Dec; 1(3):149-52. PubMed ID: 2484879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine (131I) therapy for hyperthyroid Graves' disease.
    Kaise K; Kaise N; Yoshida K; Fukazawa H; Mori K; Yamamoto M; Sakurada T; Saito S; Yoshinaga K
    Endocrinol Jpn; 1991 Aug; 38(4):429-33. PubMed ID: 1687028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.